Drastically reducing sample processing time, new SPARCL technology increases our capacity for large molecule bioanalysis.
Our new FT-IR spectrometer allows us to provide a more comprehensive package for protein higher order structural characterization.
Following redevelopment, our Lyon facility now boasts flexible housing for different species within a single building.
We’ve partnered with the global leader in aquaculture diagnostics and monitoring to extend our portfolio of zebrafish testing services in North America.
Combined ligand- and structure-based virtual screens are a successful hit finding approach in the discovery of LRRK2 inhibitors.
Charles River has further strengthened our product portfolio through a licensing agreement with SenzaGen, allowing us to incorporate SenzaGen’s GARDskin® genome test into our skin sensitization strategy.
In 1947, Dr. Henry Foster founded Charles River with a mission to support researchers and their quest for a cure. This May, Jim Foster celebrated his father’s legacy by ringing the NYSE opening bell to honor the company’s 70th anniversary.
Charles River scientists joined discovery researchers from around the world for the annual meeting of the ATS in D.C. this May. Their contribution to the conference included three posters on the use of imaging and iPSCs in pulmonary disease research and innovative clinical trial designs.
Reprofiling an abandoned compound series, or repurposing a marketed compound, can mean a shorter time-to-market for new treatments. Here we look at some examples from our respiratory team archives.
The Genetic Toxicology Association and the Environmental Mutagen & Genomics Society acknowledge scientists and their contributions to the field.